Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Extended Access of Momelotinib in Adults With Myelofibrosis
Back

Extended Access of Momelotinib in Adults With Myelofibrosis

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Cardiff London Bristol Cardiff Airdrie Bristol Airdrie London Oxford. Oxford

Medical Conditions

Polycythemia Vera
Primary Myelofibrosis
Polycythemia
Thrombocytosis
Thrombocythemia, Essential

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies GS-US-352-0101 (NCT01969838), GS-US-352-1214 (NCT02101268), GS-US-352-1154 (NCT02124746), SRA-MMB-301 who are currently receiving treatment with MMB (available as 50mg,100 mg, 150 mg and 200 mg tablets) and have not experienced progression of disease. The secondary objective is to assess overall survival (OS) and leukemia free survival (LFS) in all subjects.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

May 2018 Dec 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Tablet(s) administered orally once daily

Intervention Arm Group : Cohort 1: Study GS-US-352-0101;Cohort 2: Study GS-US-352-1214;Cohort 3: Study GS-US-352-1154;Cohort 4: Study SRA-MMB-301;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University Hospital of Wales
    Cardiff
    CF14 4XW
  • GSK Investigational Site
    London
    W12 0HS
  • GSK Investigational Site
    Bristol
    BS2 8ED
  • GSK Investigational Site
    Cardiff
    CF14 4XW
  • GSK Investigational Site
    Airdrie
    Lanarkshire
    ML6 0JS
  • University Hospitals Bristol and Weston NHS Foundation Trust
    Bristol
    England
    BS2 8ED
  • NHS Lanarkshire
    Airdrie
    Scotland
    ML6 0JS
  • Imperial College Healthcare NHS Trust
    London
    W12 ONN
  • GSK Investigational Site
    Oxford.
    OX3 7LE
  • Oxford University Hospitals NHS Trust
    Oxford
    OX3 7LJ


The study is sponsored by GlaxoSmithKline



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT03441113
Last updated 15 May 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top